GeneMedicine and Medi-Ject Collaborate on Needle-Free Injection Devices

Strategic Insights

Aug 8, 1995 — 1 min read

GeneMedicine, a Texas-based company, has partnered with Medi-Ject Corp. to develop needle-free injection devices for the delivery of therapeutic genes to specific tissues. This collaboration aims to enhance the delivery of gene therapies for various diseases and disorders. The partnership brings together GeneMedicine's cutting-edge gene technologies with Medi-Ject's expertise in needle-free injection systems.

Key Takeaways:

GeneMedicine is developing a new class of pharmaceutical products called "gene medicines" using two technologies: plasmid gene expression systems and synthetic gene delivery systems.
These technologies have potential applications in treating genetic and acquired diseases, including blood, muscle, inflammatory, pulmonary, cardiovascular, and metabolic disorders, as well as cancers and gene vaccines.
GeneMedicine has corporate partnerships with Roche Bioscience and Boehringer Mannheim for the development of gene medicines in areas such as arthritis, asthma, transplant rejection, and cancer.
The Medi-Jector, a needle-free injection system developed by Medi-Ject, has delivered over 87 million insulin injections worldwide, making it one of the largest selling injectors for insulin globally.
GeneMedicine's technologies have the potential to revolutionize the delivery of genetic therapies and improve treatment outcomes for patients suffering from various diseases.

Statistics:

Over 87 million insulin injections have been given with the Medi-Jector.
GeneMedicine is developing products through corporate alliances with major biotechnology and pharmaceutical companies, including Roche Bioscience and Boehringer Mannheim.
GeneMedicine's technologies are designed to control the location and function of therapeutic genes within the body, with potential applications in treating a wide range of genetic and acquired diseases.

Sources:

Business Wire, "GeneMedicine Inc. and Medi-Ject Corp. Form Research and Development Agreement"
(no date specified)
Measures and quotes provided are taken directly from the original document.

The End of American Hypergrowth

For two centuries, the US economy grew by adding workers. That's over.

Healthcare's $5.3 Trillion Drag

How Medical Spending Became America's Biggest Productivity Tax

Breakthrough in Nanotechnology: Electromagnetic Shock Treatment Shows Promise

Researchers at the Wuhan University of Technology in China have made significant progress in the field of nanotechnology, specifically in the area of nanoindentation. A novel electromagnetic shock treatment (EST) method has been developed to enhance the microscale mechanical properties of a titanium alloy, with promising results obtained through array-based

Gut Microbiota Plays Crucial Role in Immunotherapy Success for Colon Cancer Patients

Research investigators at the Zhengzhou Central Hospital Affiliated to Zhengzhou University have made groundbreaking discoveries on the role of gut microbiota in determining the efficacy of immunotherapy for colon cancer patients. The study, which was recently published in Biochimica et Biophysica Acta, reveals that specific bacterial species and microbial metabolites

Read more

The End of American Hypergrowth

Healthcare's $5.3 Trillion Drag

Breakthrough in Nanotechnology: Electromagnetic Shock Treatment Shows Promise

Gut Microbiota Plays Crucial Role in Immunotherapy Success for Colon Cancer Patients